Clinical trials: Multi Cancer Early Screening
Neoplasms, Cancer
PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection
Liquid biopsy technology based on cell-free nucleic acids and protein characteristics has unique advantages and significant application prospects in cancer early detection.
- Trial name
- PROFUTURE (NCT05874648)
- Testing
- Multi-cancer early detection test
- Where
- China
- Volunteers
- 3,830 people, healthy volunteers welcome
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Neoplasms, Solid Tumor
Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
DNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict…
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Lung Neoplasms
- Trial name
- METHYLSCAPE-CO (NCT07741435)
- Testing
- Methylscape DNA methylation assay
- Where
- Colombia
- Volunteers
- 3,250 people, healthy volunteers welcome
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Thoracic Cancer, Ovarian Cancer
Project CADENCE (CAncer Detected Early caN be CurEd)
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be…
- Conditions
- Thoracic Cancer, Ovarian Cancer, Liver Cancer, Prostate Cancer
- Trial name
- CADENCE (NCT05633342)
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiRXES Pte Ltd
Lung Cancers, Liver Cancer
AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the…
- Conditions
- Lung Cancers, Liver Cancer, Gastric Cancers, Colorectal, Cancer
- Trial name
- NCT06632886
- Testing
- AI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Where
- China
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Guo ShiWei
Breast Cancer
What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol
This study aims to identify key benefits and harms of integrating risk stratification (the BC-Predict intervention) into the NHS Breast Screening Programme.
- Trial name
- NCT04359420
- Testing
- BC-Predict, NHS Breast Screening Programme
- Where
- United Kingdom
- Volunteers
- 32,298 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Neoplasms, Cancer
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early.
- Trial name
- NCT03085888
- Where
- 35 sites in United States
- Volunteers
- 99,481 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Non-invasive and Sensitive Faecal Bacterial Markers for Early Screening and Diagnosis of Gastric Cancer
Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
In this clinical trial, we aim to explore the synergistic alteration of specific bacteria both in gastric mucosas and feces of gastric cancer patients for the method of non-invasive and cost-effective faecal marker detection.
- Trial name
- NCT04638959
- Testing
- collect gastric tissue and stool samples
- Where
- 10 sites in China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cancer, Lung Cancer
The SUMMIT Study: A Cancer Screening Study
The SUMMIT Study will enrol 13,000 participants in order to investigate how cancer screening can be improved and delivered. The SUMMIT Study has two main aims: the first is to clinically validate a blood test for detecting…
- Trial name
- SUMMIT (NCT03934866)
- Testing
- Low Dose CT scan
- Where
- United Kingdom
- Volunteers
- 13,035 people, healthy volunteers welcome
- Sponsor
- University College, London
Early Detection of Cancer, Cancer
PATHFINDER 2: A Multi-Cancer Early Detection Study
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America.
- Trial name
- NCT05155605
- Testing
- Multi-Cancer Early Detection Test
- Where
- 56 sites in United States, Canada
- Volunteers
- 35,883 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Colorectal Cancer, Grastic Cancer
Feasibility of Multi-cancer Early Detection Test in Screening Population (NQMD-CS)
This is a prospective, multicenter screening cohort study designed to evaluate the feasibility of a blood-based multi-cancer early detection (MCED) test in an asymptomatic screening population.
- Conditions
- Colorectal Cancer, Grastic Cancer, Esophageal Cancer, Lung Cancer
- Trial name
- NCT07834268
- Testing
- MCED
- Where
- 2 sites in China
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Fifth Affiliated Hospital of Guangzhou Medical University
Hematologic Malignancy
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM)…
- Trial name
- SANGUINE (NCT05735704)
- Testing
- Blood sampling for HemaChip screening/diagnostic testing
- Where
- 4 sites in Czechia, Greece and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Cancer
Development and Validation of Harbinger Health Test for Early Cancer Detection
This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States.
- Trial name
- CORE-HH (NCT05435066)
- Testing
- Harbinger Health Test
- Where
- 128 sites in United States
- Volunteers
- 8,038 people, healthy volunteers welcome
- Sponsor
- Harbinger Health
Nasopharyngeal Carcinoma (NPC)
Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: cfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection
This study focus on nasopharyngeal carcinoma, a cancer type with Chinese characteristics, analyze the early screening detection performance of nasopharyngeal carcinoma in the multi-cancer early screening model, and compare the…
- Trial name
- PROFOUND-NPC (NCT06763289)
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer
A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
- Trial name
- NCT03693378
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 1,349 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Colorectal Cancer
Establishment and Clinical Validation of New Technologies for Accurate Screening of Colorectal Cancer Based on Multi-omics
Background: The current screening techniques for colorectal cancer include colonoscopy, fecal occult blood, and high-risk factor questionnaires.
- Trial name
- NCT04913233
- Where
- 3 sites in China
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Stomach Cancer
Development of Free DNA Multi-target Methylated PCR for Auxiliary Diagnosis of Gastric Cancer
This was a case control, non-intervention study jointly developed by Fudan University Cancer Hospital and Shanghai Singlera Genomics Company.
- Trial name
- NCT05336058
- Testing
- No intervention
- Where
- China
- Volunteers
- 1,140 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Colorectal Adenoma, Colorectal Cancer
Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence
To evaluate the accuracy and effectiveness of a novel screening method based on plasma multi-omics combining with artificial intelligence in a large prospective cohort for the detection of colorectal cancer and advanced adenomas.
- Trial name
- RECOMMEND (NCT05587452)
- Testing
- Colonoscopy, Test of ctDNA methylation, Test of characteristics of ctDNA fragment
- Where
- 5 sites in China
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences